Department of Medical Gastroenterology, Asian Institute of Gastroenterology, Hyderabad, India.
Aliment Pharmacol Ther. 2018 May;47(10):1367-1374. doi: 10.1111/apt.14617. Epub 2018 Mar 24.
The diagnosis of Crohn's disease (CD) can be delayed in clinical practice. In tuberculosis endemic areas, empirical anti-tubercular therapy further delays treatment.
AIM(S): To assess risk factors for diagnostic delay and its impact on the long-term complications of Crohn's disease in India where tuberculosis is endemic.
Data from a large prospectively established inflammatory bowel disease registry were analysed retrospectively. The time from onset of symptoms to diagnosis (diagnostic delay) was calculated and categorised into two groups based on median diagnostic delay. The risk factors for delay including anti-tubercular therapy were analysed. Logistic regression analysis was done to assess impact of diagnostic delay on development of stenotic and fistular complications including need for surgery.
Seven hundred and twenty Crohn's disease patients (60.3% male, median: 28 years) were included. Main outcome measures were stenosis, fistula and need for surgery. Subjects with diagnostic delay >18 months (median) developed significantly higher stenotic complications and surgery (OR 4.12; 95% CI: 2.74-6.33, P < 0.001 and OR 2.41, 95% CI: 1.68-3.42, P < 0.001), respectively, compared to those ≤18 months. There was no difference in the development of fistulous complications. 193/720 (27%) received anti-tubercular therapy which significantly contributed to diagnostic delay (OR: 2.47; 95% CI: 1.76-3.47, P < 0.001) with 47% showing initial clinical response (Crohn's disease activity index- CDAI decrease >100). Moreover, the incidence of stenotic complications was significantly higher in patients who had received prior anti-tubercular therapy (55/193 (28.49%) vs 78/527 (14.8%), P < 0.001, OR: 2.60, 95% CI: 1.64-4.12).
Diagnostic delay in Crohn's disease is associated with significantly higher stenotic complications and need for surgery. Empirical anti-tubercular therapy is the single largest contributor to diagnostic delay in tuberculosis endemic areas. Despite initial clinical response to anti-tubercular therapy, long-term stenotic complications are higher.
在临床实践中,克罗恩病(CD)的诊断可能会被延误。在结核病流行地区,经验性抗结核治疗进一步延迟了治疗。
评估诊断延迟的风险因素及其对印度(结核病流行地区)克罗恩病长期并发症的影响。
回顾性分析了一个大型前瞻性炎症性肠病登记处的数据。计算从症状发作到诊断的时间(诊断延迟),并根据中位数诊断延迟将其分为两组。分析包括抗结核治疗在内的延迟的风险因素。使用逻辑回归分析评估诊断延迟对狭窄和瘘管并发症发展(包括手术需要)的影响。
共纳入 720 例克罗恩病患者(60.3%为男性,中位年龄:28 岁)。主要结局指标为狭窄、瘘管和手术需要。诊断延迟>18 个月(中位数)的患者显著更易发生狭窄性并发症和手术(OR 4.12;95%CI:2.74-6.33,P<0.001 和 OR 2.41,95%CI:1.68-3.42,P<0.001),与≤18 个月的患者相比。两组患者瘘管并发症的发展无差异。720 例患者中有 193 例(27%)接受了抗结核治疗,这显著导致了诊断延迟(OR:2.47;95%CI:1.76-3.47,P<0.001),其中 47%的患者有初始临床反应(克罗恩病活动指数-CDAI 下降>100)。此外,接受过抗结核治疗的患者狭窄性并发症的发生率显著更高(55/193(28.49%)比 78/527(14.8%),P<0.001,OR:2.60,95%CI:1.64-4.12)。
克罗恩病的诊断延迟与更严重的狭窄性并发症和手术需要显著相关。经验性抗结核治疗是结核病流行地区导致诊断延迟的最大单一因素。尽管抗结核治疗有初始临床反应,但长期狭窄性并发症的发生率更高。